Literature DB >> 8229065

Evidence for autoimmunity in amyotrophic lateral sclerosis.

S H Appel1, R G Smith, J I Engelhardt, E Stefani.   

Abstract

Although the etiology and pathogenesis of ALS is unknown, increasing evidence supports a role for autoimmune mechanisms in motoneuron degeneration and death. An animal model, experimental autoimmune gray matter disease, can be induced by the inoculation of spinal cord gray matter. The experimental disease is characterized by weakness secondary to the loss of upper and lower motoneurons, accompanied by inflammatory foci within the spinal cord, and IgG at the neuromuscular junction and within UMN and LMN. In human ALS, IgG is present within the UMN and LMN, and T-lymphocytes and activated microglia have been identified within spinal cord gray matter and motor cortex. ALS IgG can passively transfer physiological changes of the neuromuscular junction to mice resulting in enhanced release of acetylcholine. The ALS IgG selectively interact with calcium channels and alter channel function. These data suggest a potential role for autoimmune mechanisms in the destruction and loss of motoneurons in ALS.

Entities:  

Mesh:

Year:  1993        PMID: 8229065     DOI: 10.1016/0022-510x(93)90106-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  18 in total

Review 1.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

2.  Localization of Ca2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals.

Authors:  R E Westenbroek; L Hoskins; W A Catterall
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

Review 3.  Glutamate, excitotoxicity and amyotrophic lateral sclerosis.

Authors:  P J Shaw; P G Ince
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

Review 4.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 5.  Differential contribution of microglia and monocytes in neurodegenerative diseases.

Authors:  Caroline Baufeld; Elaine O'Loughlin; Narghes Calcagno; Charlotte Madore; Oleg Butovsky
Journal:  J Neural Transm (Vienna)       Date:  2017-10-23       Impact factor: 3.575

Review 6.  Motor neuron-immune interactions: the vicious circle of ALS.

Authors:  Ana G Barbeito; Pinar Mesci; Séverine Boillée
Journal:  J Neural Transm (Vienna)       Date:  2010-06-15       Impact factor: 3.575

7.  Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes.

Authors:  Shulamit Naor; Zohar Keren; Tomer Bronshtein; Efrat Goren; Marcelle Machluf; Doron Melamed
Journal:  J Neurol       Date:  2009-03-12       Impact factor: 4.849

Review 8.  The pre-synaptic motor nerve terminal as a site for antibody-mediated neurotoxicity in autoimmune neuropathies and synaptopathies.

Authors:  Simon N Fewou; Jaap J Plomp; Hugh J Willison
Journal:  J Anat       Date:  2013-08-13       Impact factor: 2.610

9.  No association between biopsy-verified celiac disease and subsequent amyotrophic lateral sclerosis--a population-based cohort study.

Authors:  J F Ludvigsson; D Mariosa; B Lebwohl; F Fang
Journal:  Eur J Neurol       Date:  2014-04-07       Impact factor: 6.089

10.  Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study.

Authors:  Martin R Turner; Raph Goldacre; Sreeram Ramagopalan; Kevin Talbot; Michael J Goldacre
Journal:  Neurology       Date:  2013-08-14       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.